Is autoimmunity the Achilles' heel of cancer immunotherapy?

June, Carl H, Warshauer, Jeremy T, Bluestone, Jeffrey A·2017·Nature Medicine
DOI 10.1038/nm.4321

Cited by (445)

Items 301–400 of 445

  1. The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab
    Katherine E R Smith, Stephanie L. Pritzl, Wei Yu, Ilze Bāra, Gita Thanarajasingam, Monika D. Kaul, Kirstin Anne Williams, Amylou Constance Dueck, Aaron Scott Mansfield · 2023 · JTO Clinical and Research Reports
  2. Prediction of immunotherapy response using mutations to cancer protein assemblies
    JungHo Kong, Xiaoyu Zhao, Akshat Singhal, Sungjoon Park, Robin E. Bachelder, Jeanne Shen, Haiyu Zhang, J. Moon, Chang-Ho Ahn, Chan‐Young Ock et al. · 2024 · Science Advances
  3. Immune Cell Infiltration into the Eye Is Controlled by IL-10 in Recoverin-Induced Autoimmune Retinopathy
    Enayat Nikoopour, Cheng‐mao Lin, Sarah Sheskey, John R. Heckenlively, Steven K. Lundy · 2019 · The Journal of Immunology
  4. Safety of Immune Checkpoint Blockade in Patients with Cancer and Preexisting Autoimmune Diseases and/or Chronic Inflammatory Disorders
    Mohsin Shah, Mazen Jizzini, Imad El Majzoub, Aiham Z. Qdaisat, Cielito C. Reyes‐Gibby, Sai‐Ching J. Yeung · 2019 · Journal of Immunotherapy and Precision Oncology
  5. Optimal CAR T-cell Immunotherapy Strategies for a Leukemia Treatment Model
    Evgenii Nikolaevich Khailov, Ellina Valerievna Grigorieva, Anna D. Klimenkova · 2020 · Games
  6. Antitumor efficacy of MUC1-derived variable epitope library treatments in a mouse model of breast cancer
    Josué Odales, Rodolfo Servín-Blanco, Fernando Martínez‐Cortés, Jesus Guzman Valle, Allan Noé Domínguez‐Romero, Goar Gevorkian, Karen Manoutcharian · 2022 · Vaccine
  7. Ocular Immune-Related Adverse Events Associated with PD-1 Inhibitors: From Molecular Mechanisms to Clinical Management
    Yuqi Gong, Yushuai Liu, Fagang Jiang, Xinghua Wang · 2024 · Seminars in Ophthalmology
  8. Cardiotoxicity of T cell immunotherapies
    Michael A. Raddatz, Ashley F. Stein-Merlob, Syed S. Mahmood, Sarju Ganatra, Daniel Addison, Tasha Lotus Lin, Sarah Marie Larson, Eric H. Yang · 2026 · Nature Reviews Cardiology
  9. Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know
    Mohsin Shah, Eva Rajha, Courtney Denton Dinardo, Erin Muckey, William G. Wierda, Sai‐Ching J. Yeung · 2019 · Annals of Emergency Medicine
  10. Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections
    Christina R. Schmitt, Esmée P. Hoefsmit, T. Fangmeier, Nora Kramer, Canan Kabakci, J. Vera González, Judith M. Versluis, Annette C Compter, Thomas Harrer, Hrvoje Mijočević et al. · 2023 · Cancer Immunology Immunotherapy
  11. B7 immune checkpoint family members as putative therapeutics in autoimmune disease: An updated overview
    Katayoun Dolatkhah, Nazila Alizadeh, Hanieh Mohajjel‐Shoja, Mahdi Abdoli Shadbad, Khalil Hajiasgharzadeh, Leili Aghebati Maleki, Amir Baghbanzadeh, Negar Hosseinkhani, Noora Karim Ahangar, Behzad Baradaran · 2022 · International Journal of Rheumatic Diseases
  12. Local tumour nanoparticle thermal therapy: A promising immunomodulatory treatment for canine cancer
    Carla Martí Castelló, Mara Taís de Carvalho, Andris Figueiroa Bakuzis, Simone Gonçalves Fonseca, Marina Pacheco Miguel · 2022 · Veterinary and Comparative Oncology
  13. Time‐to‐event calibration‐free odds design: A robust efficient design for phase I trials with late‐onset outcomes
    Huaqing Jin, Guosheng Yin · 2023 · Pharmaceutical Statistics
  14. Autoimmune Polyglandular Syndromes
    Bimota Nambam, Michael J. Haller, William E. Winter, Desmond Schatz · 2021 · Elsevier eBooks
  15. Endocrine complications of cancer immunotherapy
    Aleksandra Król, Tomasz Gawlik, Barbara Jarząb · 2018 · Endokrynologia Polska
  16. 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two
    2017 · Journal for ImmunoTherapy of Cancer
  17. Sorting Out the Complexities of Autoimmunity and Checkpoint Inhibitors: Not So Easy
    Leonard H. Calabrese · 2018 · Annals of Internal Medicine
  18. Induction of islet autoimmunity to defective ribosomal product of the insulin gene as neoantigen after anti-cancer immunotherapy leading to autoimmune diabetes
    René van Tienhoven, Diahann T. S. L. Jansen, Miso Park, John C. Williams, James Larkin, Sergio A. Quezada, Bart O. Roep · 2024 · Frontiers in Immunology
  19. Safety and Efficacy of Immune Checkpoint Inhibitors in Human Immunodeficiency Virus-Associated Cancer: A Systematic Scoping Review
    Ahmed D. Alatawi, Amirah B. Alaqyl, Reema J. Alalawi, Rahaf S. Alqarni, Razan A. Sufyani, Ghadi Saleh M Alqarni, Raghad Saleh Alqarni, Jumana H. Albalawi, Raghad A. Alsharif, Ghada I. Alatawi et al. · 2025 · Diseases
  20. Multifunctional hydrogels for synergistic therapy of cutaneous melanoma-associated tumor recurrence and wound regeneration
    Muyang Li, Yishuai Sun, Chengjun Hu, Hang Luo, Min Li, Ying Yang · 2025 · Materials Today Bio
  21. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report
    Tanja Fetter, Simon Fietz, Maya Bertlich, Christine Braegelmann, Luka de Vos‐Hillebrand, Joerg Wenzel, Annkristin Heine, Jennifer Landsberg, Philipp Jansen · 2024 · Frontiers in Immunology
  22. Cell‐intrinsic mechanisms to restrain inflammatory responses in T lymphocytes
    Emina Džafo, Niccolò Bianchi, Silvia Monticelli · 2021 · Immunological Reviews
  23. ROCKETS – a novel one-for-all toolbox for light sheet microscopy in drug discovery
    Joerg Mueller, Michael Dobosz, Nils O’Brien, Nassri Abdoush, Anna Maria Giusti, Martin Lechmann, Franz Osl, Ann‐Katrin Wolf, Estibaliz Arellano-Viera, Haroon Shaikh et al. · 2023 · Frontiers in Immunology
  24. Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?
    Madhav V. Dhodapkar, Kavita M. Dhodapkar · 2019 · Frontiers in Immunology
  25. Disparities in Utilization of Immune Checkpoint Inhibitor Therapy Among Older Patients With Advanced Non–Small Cell Lung Cancer: A SEER-Medicare Analysis
    Danting Yang, Shama D. Karanth, Hyung‐Suk Yoon, Jae Jeong Yang, Xiwei Lou, Jiang Bian, Dongyu Zhang, Yi Maggie Guo, Lusine Yaghjyan, Tomi Akinyemiju et al. · 2024 · JCO oncology advances.
  26. Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy
    Heinz Philipp Laubli, Stefan Dirnhofer, Alfred Zippelius · 2018 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  27. Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity
    Louis F. Chai, John C. Hardaway, Kara R. Heatherton, Kyle P. O’Connell, Mikayla C Lopes, Benjamin A. Rabinowitz, Chandra C. Ghosh, Prajna Guha, David Jaroch, Bryan F. Cox et al. · 2021 · Vaccines
  28. Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes
    Anže Smole · 2022 · Radiology and Oncology
  29. Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review
    Loulu Gao, Xuemei Li, Zhijun Guo, Lin Tang, Jieqiong Peng, Bo Liu · 2022 · Medicine
  30. Dynamic toxicity landscape of immunotherapy for solid tumors across treatment lines
    Lihui Liu, Sini Li, Guoqiang Wang, Yan Qu, Zhijie Wang, Jianchun Duan, Chao Wang, Pei Xue, Xue Zhang, Zixiao Ma et al. · 2023 · Journal of the National Cancer Center
  31. Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia
    S Jo, J H Lee, Jane Mattei, David Maxwell Barrett, Peter van den Elzen, Stephan A. Grupp, Gregor S. D. Reid, Alix Eden Seif · 2017 · Leukemia
  32. A gut punch fights cancer and infection
    Nathan Edward Reticker-Flynn, Edgar G. Engleman · 2019 · Nature
  33. Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors
    Lilian Guadalupe Cano-Cruz, Ana Barrera‐Vargas, Abigail Mateos-Soria, Enrique Soto‐Pérez‐de‐Celis, Javier Merayo‐Chalico · 2021 · Archives of Medical Research
  34. Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report
    Guo Hong, Haina Zhao, Yuxuan Yin, Hailin Shen, Zhaohao Zeng, Jianwei Yang, Lili Zhang · 2023 · Frontiers in Immunology
  35. Immunologic adverse events from immune checkpoint therapy
    Michael D. Richter, Grant C. Hughes, Sarah H. Chung, Mary Ezeanuna, Namrata Singh, John A. Thompson · 2020 · Best Practice & Research Clinical Rheumatology
  36. Polymersome-based nanomedicine for combined cancer therapy
    Aidin Mohammadi Zonouz, Mehrshad Ebrahimpour, Kimia Zibaei, Mohammad Ramezani, Sahar Taghavi, Khalil Abnous, Seyed Mohammad Taghdisi, Mona Alibolandi · 2025 · Drug Delivery
  37. Risk Factors and Biomarkers for Pulmonary Toxicities Associated with Immune Checkpoint Inhibitors
    Efraim Güzel, İsmail Hanta, Oya Baydar, Okan Gurbuz, Burak Mete, Ertuğrul Bayram · 2025 · Medicina
  38. Immune Checkpoint Inhibition—Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity
    Uma Thanarajasingam, Noha Abdel‐Wahab · 2020 · Rheumatic Disease Clinics of North America
  39. The Search for a Universal Influenza Vaccine: Possibilities and Limitations
    E. P. Kharchenko · 2019 · Epidemiology and Vaccinal Prevention
  40. Drug loaded nanomaterials for hematological malignancies diagnosis and enhanced targeted therapy
    Priyanka Samal, Shahani Begum · 2022 · Elsevier eBooks
  41. Combinaisons d’inhibiteurs de points de contrôle immunitaires en oncologie : état de l’art et perspectives
    Chloé Dussart, Baptiste Decaux-Tramoni, Stanislas Quesada, Quentin Dominique Thomas, Ouail Benzerouale, Emanuel Nicolas, Frédéric Fiteni · 2023 · Bulletin du Cancer
  42. Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists
    Sang Taek Kim, Maria Eugenia Suarez-Almazor · 2018 · Expert Review of Clinical Immunology
  43. Time-to-Event Model-Assisted Designs to Accelerate Phase I Clinical Trials
    Ruitao Lin, Ying Yuan · 2018 · arXiv (Cornell University)
  44. Analysis of the safety and efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy in the treatment of locally advanced resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis based on four randomized controlled trials
    Tao Luo, Hao Yang, Xingqiang Ran, Benhua Xu, Yue Zhang, Liwen Zhang, Chengcheng Zhang, Maoyong Fu · 2025 · Frontiers in Oncology
  45. Lung Toxicity from Immune Checkpoint Inhibitors: A Diagnostic Approach
    Ana Casal, Virginia Leiro‐Fernández, Laura Villar-Aguilar, Manuel Casal-Guisande, Mar Mosteiro, Maribel Botana‐Rial, Cristina Represas‐Represas, María Torres‐Durán, Alberto Fernández‐Villar · 2025 · Journal of Clinical Medicine
  46. Autoimmune Polyglandular Syndromes
    Mark A. Sperling, Anna G. Angelousi, Mabel Yau · 2021 · MDText.com, Inc. eBooks
  47. Sicca Syndromes
    Blake M. Warner, Alan N. Baer · 2021 · Springer eBooks
  48. Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?
    Teresa Squicciarini, Rossella Villani, Benedetta Apollonio, Livia Fucci, Milena Zambetti, Michele Rossini, Rosamaria Pinto, Stefania Tommasi, Ileana De Roma, Sabino Strippoli et al. · 2024 · Frontiers in Immunology
  49. Report on the 2018 Cancer, Autoimmunity, and Immunology Conference
    Colleen S. Curran, Connie L. Sommers, Howard A. Young, Katarzyna Bourcier, Marie Mancini, Elad Sharon · 2019 · The Journal of Immunology
  50. Drug delivery systems in cancer therapy
    Bessi Qorri, Alexandria DeCarlo, Matthew Mellon, Myron R. Szewczuk · 2020 · Elsevier eBooks
  51. Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity
    Ion G. Motofei · 2021 · Expert Opinion on Drug Safety
  52. Fatal Toxicity Induced by anti-PD-1 Immune Checkpoint Inhibitor in Thymic Epithelial Tumor
    Xuquan Jing, Hui Zhu, Yuying Li, Wenxiao Jia, Xiaoyang Zhai, Ji Li, Jinming Yu · 2022 · Immunotherapy
  53. Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors
    Stefano Lucà, Marina Accardo, Severo Campione, Renato Franco · 2024 · Exploration of Targeted Anti-tumor Therapy
  54. Design and Gene Delivery Application of Polymeric Materials in Cancer Immunotherapy
    Ying Chen, Lingjie Ke, Xian Jun Loh, Yun‐Long Wu · 2022 · World Scientific Annual Review of Functional Materials
  55. Activatable Semiconducting Polymer Pro‐nanomodulators for Deep‐Tissue Sono‐immunotherapy of Orthotopic Pancreatic Cancer
    Jingchao Li, Ningyue Yu, Dong Mei Cui, Jiaguo Huang, Yu Luo, Kanyi Pu · 2023 · Angewandte Chemie
  56. Asymptomatic Brainstem Lesions and Pachymeningeal Enhancement After anti-PD-1 Therapy
    Carlen Yuen, Kourosh Rezania, Deric M. Park, Anthony T. Reder · 2020 · Immunotherapy
  57. Applications of intelligent biomaterials in cancer immunotherapy: A review
    Deepti Katiyar · 2023 · Materials Today Proceedings
  58. Eliciting a potent antitumor immune response by expressing tumor antigens in a skin commensal
    Yiyin Erin Chen, Katayoon Atabakhsh, Alex Dimas, Kazuki Nagashima, Michael Andrew Fischbach · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  59. A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance
    Mark Stuart Anderson, Jeremy T. Warshauer, Julia A. Belk, Alice Y. K. Chan, Jiaxi Wang, Alexander R. Gupta, Dante Dennis Acenas II, Quanming Shi, Yani Peng, Jonah D. Phipps et al. · 2021 · Research Square
  60. Cell Membrane Engineering for Advancing Cancer Immunotherapy
    Tong Li, Bin Liu, Cheng Dong, Yun Chang · 2025 · Springer eBooks
  61. Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
    Tessa Faye Flores, Emily S. Tonorezos, Shailender Bhatia, Julie Renee Brahmer, Laura C. Cappelli, Monica T. Cooper, Marianne J Davies, Samantha R. Guild, Krishna Soujanya Gunturu, John B.A.G. Haanen et al. · 2026 · Journal for ImmunoTherapy of Cancer
  62. Preparation Method and In Vitro Characterization of Nanoparticles Sensitive to Tumor Microenvironment
    Naym Blal, Daniela Guarnieri · 2023 · Methods in molecular biology
  63. Application of serum anti‑ENO1 and anti‑SSNA1 antibody biomarkers in predicting the prognosis of gastric cancer
    Satoshi Yajima, Masaaki Ito, Takashi Suzuki, Yoko Oshima, Makoto Sumazaki, Fumiaki Shiratori, Hirotaka Takizawa, Shu-Yang Li, Bo‐Shi Zhang, Yoichi Yoshida et al. · 2025 · Oncology Letters
  64. Identification of protein biomarker candidates associated with organ-specific immune-related toxicity and response to management by plasma proteomics
    Anders Handrup Kverneland, Ole Østergaard, Joel E Sohlin, Inge Mansfield Noringriis, Rebecca Schou Jurlander, Jesper Velgaard Olsen, Inge Marie Svane · 2025 · BMJ Oncology
  65. The battle to tame autoimmunity
    Katherine Bourzac · 2018 · Nature
  66. The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy
    Leonard H. Calabrese, Cassandra M. Calabrese · 2020 · Current Opinion in Rheumatology
  67. Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors
    Dan Zhao, Haiqing Li, Isa Mambetsariev, Chen Chen, Rebecca R. Pharaon, Jeremy Fricke, Angel Ray Baroz, Prakash Kulkarni, Yan Xing, Erminia Massarelli et al. · 2021 · Cancers
  68. Development and validation of an immune-related gene prognostic index for lung adenocarcinoma
    Zitao Liu, Yujie Lei, Junting Shen, Guangqiang Zhao, Xi Wang, Yutian Wang, Yujin Kudo, Jun Liao, Yunchao Huang, Tingdong Yu · 2023 · Journal of Thoracic Disease
  69. Editorial: Immune-checkpoint inhibitors in anti-cancer armamentarium: a double-edged sword in risk of developing autoimmunity and immune-related adverse effects
    Aysın Tulunay Virlan, Giacomo Cafaro, Flavia Sunzini, Yannick Degboé, Maria Christodoulou · 2024 · Frontiers in Oncology
  70. Outcomes and Adverse Events in Patients with Cancer after Diagnosis of Immunotherapy-Associated Diabetes Mellitus: A Retrospective Cohort Study
    Eva Duvalyan, Sam Brondfield, Robert J Rushakoff, Mark Stuart Anderson, Zoe Quandt · 2024 · Cancers
  71. An Enzyme-Responsive Imiquimod Prodrug for Precision Immune Activation within the Tumor Microenvironment
    Elsa Cannoni, Israa Al Jamal, Rony Eid, Rémi Châtre, Pauline Poinot, Isabelle Tranoy‐Opalinski, Sébastien Papot · 2025 · Bioconjugate Chemistry
  72. The role of CD26 in breast cancer and its pan-cancer analysis
    Runyi Tao, Bohao Liu, Shan Gao, Jingyi Zhang, Qiuyu Gong, Yanpeng Zhang, Peng Li, Xingzhuo Zhu, Yilong Zhao, Jiaqi Huang et al. · 2026 · BMC Cancer
  73. MLANA is a potential prognostic biomarker and correlated with immune infiltration in skin cutaneous melanoma
    Nan Tang, Xudong Lai, Weilun Wen, Yanhua Wu, Xifeng Xiong · 2026 · Clinical and Experimental Medicine
  74. Rethinking Immune Checkpoint Inhibition in Cancer
    Tibor Bakács, Colin C. Anderson · 2026 · Scandinavian Journal of Immunology
  75. Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine
    Savino Sciascia, Marie Hudson, Marvin J. Fritzler, Minoru Satoh, Michael Mähler · 2021 · Elsevier eBooks
  76. Self-assemblies with cascade effect to boost antitumor systemic immunotherapy
    Ruipeng Li, Xiaoyu Zhao, Yunxia Wang, Chenhao Guo, Zhijun Wang, Liheng Feng · 2022 · Chemical Communications
  77. Inhaled delivery of immunotherapy for treatment of lung cancer
    Amr Hefnawy, Alaa A. Ibrahim, Mahmoud M. Abdullah, Moustafa M. Abdelaziz, Islam Ahmed Hamed Khalil · 2024 · Elsevier eBooks
  78. Anticancer therapy-induced peripheral neuropathy in solid tumors: diagnosis, mechanisms, and treatment strategies
    Jiahong Jiang, Luying Zhan, Boyang Jiang, Jingyi Pan, Chaojin Hong, Zheling Chen, Liu Yang · 2025 · Cancer Letters
  79. Paraneoplastic and Other Autoimmune Disorders
    Alexander C. Mohler, Mayra Montalvo, Julie L. Roth · 2019 · Current clinical neurology
  80. Toxicities of Novel Antineoplastic Therapies
    Eva Rajha, Sai‐Ching J. Yeung · 2021 · Springer eBooks
  81. Immunoimaging
    Sikandar Shaikh · 2022 · Springer eBooks
  82. Overview of model-assisted design for phase I dose-finding trials in oncology
    Koichi Hashizume, Kentaro Takeda, Hiroyuki Sato, Akihiro Hirakawa, Takashi Sozu · 2022 · Japanese Journal of Biometrics
  83. Exploiting Autoimmunity Unleashed by an Off-Label Low-Dose Immune Checkpoint Blockade to Treat Advanced Cancer
    Tibor Bakács, Ralph W. Moss, Attila Marcell Szász, Colin C. Anderson · 2018 · Preprints.org
  84. Peptide aggregation-induced immunogenic cell death in a breast cancer spheroid model
    Gokhan Gunay, Katelyn N. Maier, Seren Hamsici, Filipa Carvalho, Tristan A. Timog, Handan Acar · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  85. Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies
    Uday Prakash Kulkarni, Marcos J. G. De Lima, Boro Dropulić, Ying Xiong, Zhongyu Zhu · 2025 · Expert Opinion on Biological Therapy
  86. Grundlagen der Krebsimmuntherapie
    Thomas Wölfel · 2017 · Der Onkologe
  87. Management immunvermittelter Nebenwirkungen
    Melanie Janning, Sonja Loges · 2017 · Info Onkologie
  88. Grundlagen der Krebsimmuntherapie
    Thomas Wölfel · 2018 · Wiener klinisches Magazin
  89. Management immunvermittelter Nebenwirkungen
    Melanie Janning, Sonja Loges · 2018 · hautnah dermatologie
  90. REOVIRUS-DRIVEN MYELOID CELLS IN ONCOLYTIC VIRUS THERAPY AND INFECTION
    Derek R. Clements · 2018 · DalSpace (Dalhousie University)
  91. Remediação das vias p53/Arf e interferon-beta como uma estratégia de imunoterapia do câncer: uma abordagem de transferência gênica
    Ruan F.V. Medrano · 2018
  92. We can learn a lot from drug adverse effects
    Brian F. Mandell · 2018 · Cleveland Clinic Journal of Medicine
  93. Can We Expect Less Toxicities with Newer Forms of Radiotherapy?
    Volker Budach, Alexander Henry Thieme · 2018 · Springer eBooks
  94. Immunopathogenesis of Immune-Related Adverse Events from Cancer Immunotherapy
    Leonard H. Calabrese · 2021 · Springer eBooks
  95. Emerging Trends in Immunomodulatory Nanomaterials Toward Cancer Therapy
    Anubhab Mukherjee, Vijay Sagar Madamsetty, Sudip Mukherjee · 2021 · Synthesis lectures on biomedical engineering
  96. The influence of monoclonal antibodies for cancer treatment on the endocrine system
    Kamil Dyrka, Daria Witasik, Agata Czarnywojtek, Katarzyna Łącka · 2021 · Postępy Higieny i Medycyny Doświadczalnej
  97. Effets indésirables rhumatologiques associés aux inhibiteurs de points de contrôle immunitaire : impact sur la survie globale
    Leslie Adda, Benjamin Batteux, Zuzana Saidak, Claire Poulet, Jean‐Philippe Arnault, Bruno Chauffert, Alice Séjourné · 2021 · Revue du Rhumatisme
  98. 738 Intratumoral administration of alum-tethered engineered inflammatory cytokines safely elicits potent local and systemic immunity
    Yash Agarwal, Karl Dane Wittrup, Darrell J. Irvine · 2021 · Journal for ImmunoTherapy of Cancer
  99. Faculty Opinions recommendation of Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer.
    Gabrielle Therese Belz · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  100. Faculty Opinions recommendation of Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.
    Xiaojing Ma · 2021 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature